Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
3.820
-0.240 (-5.91%)
Dec 20, 2024, 4:00 PM EST - Market closed
Company Description
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage.
It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024.
The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Grace Therapeutics, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Prashant Kohli |
Contact Details
Address: 103 Carnegie Center, Suite 300 Princeton, New Jersey 08540 United States | |
| Phone | 818 839 4378 |
| Website | gracetx.com |
Stock Details
| Ticker Symbol | GRCE |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001444192 |
| ISIN Number | US00439U1043 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Prashant Kohli | Chief Executive Officer and Director |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Vice President of Clinical Operations |
| Robert J. DelAversano CPA | Vice President of Finance and Principal Financial and Accounting Officer |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | 8-K | Current Report |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Oct 28, 2024 | 8-K | Current Report |
| Oct 25, 2024 | 8-K | Current Report |
| Oct 15, 2024 | EFFECT | Notice of Effectiveness |
| Oct 15, 2024 | EFFECT | Notice of Effectiveness |
| Oct 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Oct 8, 2024 | S-8 POS | Securities to be offered to employees in employee benefit plans, post-effective amendments |